Skip to main content

Peer Review reports

From: ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma

Original Submission
2 Feb 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
7 Mar 2023 Reviewed Reviewer Report
12 Mar 2023 Reviewed Reviewer Report
13 Mar 2023 Reviewed Reviewer Report
14 Mar 2023 Reviewed Reviewer Report
24 Apr 2023 Author responded Author comments - Ximing Xu
Resubmission - Version 3
24 Apr 2023 Submitted Manuscript version 3
29 Apr 2023 Author responded Author comments - Ximing Xu
Resubmission - Version 4
29 Apr 2023 Submitted Manuscript version 4
10 May 2023 Reviewed Reviewer Report
16 May 2023 Reviewed Reviewer Report
18 May 2023 Reviewed Reviewer Report
23 May 2023 Reviewed Reviewer Report
11 Jul 2023 Author responded Author comments - Ximing Xu
Resubmission - Version 5
11 Jul 2023 Submitted Manuscript version 5
21 Jul 2023 Author responded Author comments - Ximing Xu
Resubmission - Version 6
21 Jul 2023 Submitted Manuscript version 6
26 Jul 2023 Author responded Author comments - Ximing Xu
Resubmission - Version 7
26 Jul 2023 Submitted Manuscript version 7
1 Aug 2023 Reviewed Reviewer Report
1 Aug 2023 Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
2 Aug 2023 Editorially accepted
16 Aug 2023 Article published 10.1186/s12920-023-01624-6

You can find further information about peer review here.

Back to article page